Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
November 2, 2023 4:01 PM EDTGenerated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million, a 66% year-over-year increaseRaising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared to prior range of $200 - $215 millionCash and investments increased to $720 million at quarter end; expects positive free cash flow for full yearConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Nov. 2, 2023 /PRNewswire/... More
